Economics of Innovation - OHE - Page 6

We found for

The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK

Read more

Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?

Read more

Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?

Read more

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment

Read more

Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates

Read more

Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures

Read more

News
December 2018

Making the Most of Health Data to Deliver Pharmaceutical Innovation: What Are the Legal Barriers?

News
November 2018

Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe

News
November 2018

Presentations from ISPOR Europe 2018

News
October 2018

New Publication: Advanced Therapy Medicinal Products and Health Technology Assessment

Insight
September 2018

As UN General Assembly Highlights Tuberculosis Fight, Will BRICS Lead on the R&D Agenda?

News
September 2018

OHE Lunchtime Seminar: The People’s Prescription – Re-imagining Health Innovation to Deliver Public Value

News
August 2018

Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS

News
August 2018

The Impact of New Medicines in the NHS: 70 Years of Innovation

News
August 2018

Opportunity Costs of New Health Care Technologies: A Research Agenda

News
August 2018

Presentations from EuHEA 2018

00
02
03
04
05
06
07
08
09
10
00